Geode Capital Management’s Krystal Biotech KRYS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $260M | Buy |
698,993
+55,018
| +9% | +$16.4M | 0.01% | 691 |
|
|
2026
Q1 | $166M | Buy |
643,975
+32,097
| +5% | +$8.54M | 0.01% | 808 |
|
|
2025
Q4 | $151M | Buy |
611,878
+634
| +0.1% | +$133K | 0.01% | 846 |
|
|
2025
Q3 | $108M | Sell |
611,244
-8,303
| -1% | -$1.24M | 0.01% | 1018 |
|
|
2025
Q2 | $85.2M | Buy |
619,547
+7,194
| +1% | +$1.06M | 0.01% | 1121 |
|
|
2025
Q1 | $110M | Buy |
612,353
+20,757
| +4% | +$3.49M | 0.01% | 923 |
|
|
2024
Q4 | $92.7M | Sell |
591,596
-35
| -0% | -$6.21K | 0.01% | 1053 |
|
|
2024
Q3 | $108M | Buy |
591,631
+11,411
| +2% | +$2.2M | 0.01% | 947 |
|
|
2024
Q2 | $107M | Buy |
580,220
+54,475
| +10% | +$9.15M | 0.01% | 885 |
|
|
2024
Q1 | $93.6M | Buy |
525,745
+14,499
| +3% | +$2.01M | 0.01% | 957 |
|
|
2023
Q4 | $63.4M | Buy |
511,246
+28,011
| +6% | +$3.11M | 0.01% | 1188 |
|
|
2023
Q3 | $56.1M | Buy |
483,235
+38,975
| +9% | +$4.76M | 0.01% | 1156 |
|
|
2023
Q2 | $52.2M | Buy |
444,260
+13,689
| +3% | +$1.4M | 0.01% | 1209 |
|
|
2023
Q1 | $34.5M | Buy |
430,571
+18,444
| +4% | +$1.45M | ﹤0.01% | 1442 |
|
|
2022
Q4 | $32.6M | Buy |
412,127
+12,865
| +3% | +$955K | ﹤0.01% | 1445 |
|
|
2022
Q3 | $27.8M | Buy |
399,262
+13,887
| +4% | +$1M | ﹤0.01% | 1511 |
|
|
2022
Q2 | $25.3M | Buy |
385,375
+20,085
| +5% | +$1.25M | ﹤0.01% | 1591 |
|
|
2022
Q1 | $24.3M | Buy |
365,290
+35,364
| +11% | +$2.21M | ﹤0.01% | 1761 |
|
|
2021
Q4 | $23.1M | Buy |
329,926
+12,318
| +4% | +$717K | ﹤0.01% | 1854 |
|
|
2021
Q3 | $16.6M | Sell |
317,608
-2,568
| -0.8% | -$152K | ﹤0.01% | 2086 |
|
|
2021
Q2 | $21.8M | Buy |
320,176
+34,343
| +12% | +$2.4M | ﹤0.01% | 1902 |
|
|
2021
Q1 | $22M | Buy |
285,833
+47,126
| +20% | +$3.43M | ﹤0.01% | 1818 |
|
|
2020
Q4 | $14.3M | Buy |
238,707
+29,766
| +14% | +$1.49M | ﹤0.01% | 1920 |
|
|
2020
Q3 | $8.99M | Buy |
208,941
+28,595
| +16% | +$1.24M | ﹤0.01% | 2004 |
|
|
2020
Q2 | $7.47M | Buy |
180,346
+13,451
| +8% | +$647K | ﹤0.01% | 2106 |
|
|
2020
Q1 | $7.22M | Buy |
166,895
+20,112
| +14% | +$1.05M | ﹤0.01% | 1932 |
|
|
2019
Q4 | $8.13M | Buy |
146,783
+3,387
| +2% | +$166K | ﹤0.01% | 2156 |
|
|
2019
Q3 | $4.98M | Buy |
143,396
+23,629
| +20% | +$1.06M | ﹤0.01% | 2381 |
|
|
2019
Q2 | $4.82M | Buy |
119,767
+48,069
| +67% | +$1.57M | ﹤0.01% | 2417 |
|
|
2019
Q1 | $2.36M | Buy |
71,698
+11,095
| +18% | +$262K | ﹤0.01% | 2761 |
|
|
2018
Q4 | $1.26M | Buy |
60,603
+24,137
| +66% | +$505K | ﹤0.01% | 3009 |
|
|
2018
Q3 | $641K | Hold |
36,466
| – | – | ﹤0.01% | 3376 |
|
|
2018
Q2 | $542K | Buy |
+36,466
| New | +$410K | ﹤0.01% | 3413 |
|
Other funds holding KRYS
ACA
SCM
HRCM
Geode Capital Management's KRYS Position: Q2 2026 in Review
Geode Capital Management increased its Krystal Biotech (KRYS) stake by 8.5% in Q2 2026, buying an estimated $16.4M and bringing the position to 698,993 shares worth $260M. The position accounts for 0.01% of the portfolio, ranked #691.
Geode Capital Management first reported a position in KRYS in Q2 2018 and has held it in 33 quarters since. 398 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.
- Geode Capital Management held 698,993 shares of Krystal Biotech worth $260M as of Q2 2026.
- Geode Capital Management bought 55,018 Krystal Biotech shares in Q2 2026, an estimated $16.4M.
- Krystal Biotech made up 0.01% of Geode Capital Management's portfolio in Q2 2026, its #691 holding.
- Geode Capital Management first reported a position in Krystal Biotech in Q2 2018 and has held it in 33 quarters since.
- 398 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.